After a diagnosis of long COVID, patients in Colorado shifted from seeking care in hospitals and emergency departments (EDs) ...

Though long COVID, or post-acute sequelae of SARS-CoV-2 (PASC), is more common in adults than in kids, 1.3% of US children ...

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Developing a robust approach to mitigating the current opioid crisis in the USA will require translating novel evidence-based, neuroscience-informed treatments into clinical care and public policy.

According to the NHS, a hacking cough is the primary symptom of the illness. One clear distinction is that a ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

The FDA said clinical trials had showed that Jounavx reduced pain after surgery, and called its approval "an important public ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...